

Bit Market Services

Informazione Regolamentata n. 0472-21-2016	Data/Ora Ricezione 24 Marzo 2016 12:48:36	MTA - Star
--	---	------------

Societa' : BB BIOTECH

Identificativo : 71416

Informazione
Regolamentata

Nome utilizzatore : BIOTECHNSS01 - Alderuccio

Tipologia : AIOS 04

Data/Ora Ricezione : 24 Marzo 2016 12:48:36

Data/Ora Inizio : 24 Marzo 2016 13:03:37

Diffusione presunta

Oggetto : The Swiss Register of Commerce
registered the resolution. The stock split will
be effective starting from March 29, 2016

Testo del comunicato

Vedi allegato.

Media Release of March 24, 2016

BB Biotech AG: The Swiss Register of Commerce registered the resolution. The stock split will be effective starting from March 29, 2016

BB Biotech AG announces to have received confirmation that the Swiss Register of Commerce registered the resolution on March 24, 2016. The 5-for-1 stock split, approved by the General Meeting on March 17, 2016, will be effective starting from March 29, 2016. The new shares par value will be 0.20 CHF.

Investor Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00

Dr. Silvia Schanz, ssc@bellevue.ch

Maria-Grazia Iten-Alderuccio, mga@bellevue.ch

Claude Mikkelsen, cmi@bellevue.ch

Media Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00

Tanja Chicherio, tch@bellevue.ch

b-public AG, Pfingstweidstrasse 6, 8005 Zurich, Switzerland, Tel. +41 79 423 22 28

Thomas Egger, teg@b-public.ch

www.bbbiotech.com

Company profile

BB BIOTECH invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Disclaimer

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.

Fine Comunicato n.0472-21

Numero di Pagine: 3